Fosamax Cost in North Carolina 2026: What You Will Actually Pay

What Does Fosamax Cost in North Carolina in 2026?

Generic alendronate 70 mg tablets run about $15 per month at most North Carolina retail pharmacies in 2026. Brand-name Fosamax is priced near $80 per month at the manufacturer level, though commercial insurance and discount cards routinely cut that figure. Patients paying fully out of pocket almost never need to pay the brand list price.

Alendronate belongs to the bisphosphonate class. The FDA first approved it for postmenopausal osteoporosis in 1995 under the brand name Fosamax, and the patent has long since expired, giving North Carolina residents access to multiple generic manufacturers [1]. The standard regimen is one 70 mg tablet taken orally once weekly, on an empty stomach with 8 oz of plain water, followed by 30 minutes of upright posture before eating [2].

The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 postmenopausal women with low femoral neck bone density), found that alendronate reduced the risk of any clinical fracture by 28% over a mean 2.9 years compared with placebo (hazard ratio 0.72; P<0.001) [3]. Hip fracture risk dropped by 51% in the high-fracture-risk subgroup [3]. That efficacy record is why guidelines continue to place alendronate as a first-line agent despite the market being decades old.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend alendronate as a first-line oral agent for postmenopausal osteoporosis, citing its 10-year safety record and low cost [4]. The Endocrine Society similarly lists oral bisphosphonates as preferred initial therapy for most patients with T-score <-2.5 or a prior fragility fracture [5].

Because generic availability keeps prices low, most North Carolina patients can access alendronate without assistance programs. The sections below break down every payment pathway.

Generic vs. Brand: Understanding the Price Gap in NC

Generic alendronate accounts for the vast majority of prescriptions dispensed in North Carolina. The price gap between generic and brand is large.

At major chains in the state, including CVS, Walgreens, Walmart, and Food Lion pharmacy, GoodRx-assisted prices for 4 tablets (a one-month supply of the weekly 70 mg dose) typically fall between $10 and $18 in 2026 [6]. Walmart's $4/$10 generic list covers alendronate 70 mg at select locations, making it one of the least expensive prescription fills available anywhere [7]. Harris Teeter and Publix pharmacy programs in the Charlotte and Research Triangle markets have offered alendronate for under $12 per month as part of their generic drug programs.

Brand Fosamax, by contrast, carries a Merck list price of approximately $80 per month. Without insurance or a coupon, that translates to roughly $960 per year for a drug with an equally effective $180-per-year generic substitute. The FDA's Orange Book confirms therapeutic equivalence between brand and generic formulations [8].

A 2022 analysis in the Annals of Internal Medicine found that branded bisphosphonates were dispensed at a rate 4.3 times higher than expected given generic availability, suggesting prescriber habit and pharmacy substitution practices vary considerably by region [9]. North Carolina patients should explicitly ask their pharmacist for the generic if the brand is filled by default.

North Carolina Medicaid Coverage for Alendronate

NC Medicaid does not cover alendronate for osteoporosis as of 2026. Coverage is limited to specific diabetic bone disease contexts and does not extend to the standard postmenopausal or glucocorticoid-induced osteoporosis indications that most patients present with.

NC Medicaid's preferred drug list (PDL), maintained by the NC Division of Medical Assistance, places oral bisphosphonates outside the covered formulary for osteoporosis [10]. Patients enrolled in NC Medicaid who need alendronate for fracture prevention must currently rely on manufacturer programs, 340B pricing through eligible clinics, or compounding options described below.

This coverage gap matters because osteoporosis disproportionately affects low-income older women. The National Osteoporosis Foundation estimates that roughly 10.2 million Americans have osteoporosis and another 43.4 million have low bone mass, with women over 65 bearing the largest burden [11]. NC Medicaid's exclusion of alendronate for this indication leaves a population-level gap that prescribers should plan around.

Patients enrolled in NC Health Choice (the state CHIP program) or NC Medicaid Managed Care plans (Carolina Complete Health, Healthy Blue, United Healthcare Community Plan, WellCare of North Carolina, and AmeriHealth Caritas) should request a formulary exception or prior authorization. Approval rates for exceptions citing documented T-score <-2.5 or prior fragility fracture are not published, but the AACE recommends submitting bone density results and fracture history with every exception request [4].

Medicare Part D, which is separate from state Medicaid, does cover alendronate. All Part D plans are required to include at least one drug in every therapeutic category, and bisphosphonates are well-represented across NC plan formularies [12]. The 2024 Part D redesign capped out-of-pocket drug spending at $2,000 annually, a change that benefits patients on multiple chronic-disease medications [13].

Commercial Insurance Coverage in North Carolina

Most commercial plans in North Carolina place generic alendronate on Tier 1 (the lowest cost-sharing tier), which means a 30-day supply typically costs $0 to $15 after insurance. Brand Fosamax, when covered, almost always lands on Tier 3 or Tier 4, carrying copays of $40 to $100 per month depending on the plan design.

Blue Cross NC, the state's largest commercial insurer, lists generic alendronate 70 mg as a Tier 1 preferred generic on most individual and employer group formularies [14]. Cigna, Aetna, and UnitedHealthcare NC plans follow similar tier placement for the generic. Patients on BCBS NC plans with standard deductibles often pay $0 to $10 per monthly fill once the deductible is met.

The Affordable Care Act's preventive care mandate requires non-grandfathered plans to cover USPSTF-recommended preventive services without cost-sharing. The USPSTF recommends screening for osteoporosis with bone density testing in women 65 and older and in younger postmenopausal women at increased risk [15]. Screening is covered, but the mandate does not extend to treatment medications, so cost-sharing on alendronate still applies under most plans.

Employer self-insured plans governed by ERISA can design their own drug tiers. North Carolina state employee health plans administered through the State Health Plan (a division of the NC Department of State Treasurer) cover generic alendronate at a $0 copay for most members under the 80/20 and Base plans [16].

Discount Programs and Savings Cards for Alendronate in North Carolina

Several discount pathways reduce alendronate costs for North Carolina patients who lack coverage or face high cost-sharing.

GoodRx and RxSaver frequently list prices of $10 to $15 for a four-tablet supply of generic alendronate 70 mg at NC pharmacies [6]. These are not insurance; they are negotiated discount cards accepted at most retail chains. Patients should show the coupon at the pharmacy counter before the claim is processed, since pharmacies cannot retroactively apply the discount.

NeedyMeds, the Partnership for Prescription Assistance, and RxAssist maintain databases of manufacturer patient assistance programs (PAPs). Merck historically offered a PAP for brand Fosamax for patients below certain income thresholds, though patients who qualify for the generic at $15 per month rarely need brand-name assistance [17].

The 340B Drug Pricing Program allows federally qualified health centers (FQHCs), Ryan White HIV/AIDS Program grantees, and certain disproportionate-share hospitals in North Carolina to purchase drugs at sharply reduced prices and pass those savings to eligible patients. FQHCs in the state include Piedmont Health Services, Roanoke Chowan Community Health Center, and Community Care of Wake and Johnston counties [18]. Patients whose income falls at or below 200% of the federal poverty level and who receive care at a 340B-covered entity may access alendronate at or near $0 out of pocket.

The HealthRX NC Alendronate Cost Decision Framework matches patients to the lowest-cost pathway based on four variables: insurance status, Medicaid eligibility, 340B clinic proximity, and income level. The four tiers are:

1. Medicare Part D or commercial insurance (Tier 1 generic): target $0 to $15 per month copay.
2. No insurance, income above 200% FPL: use GoodRx or Walmart $10 generic program.
3. No insurance, income at or below 200% FPL: seek care at a 340B FQHC in NC for near-zero cost.
4. NC Medicaid only: file a formulary exception citing T-score and fracture history, and use compounded alendronate via a licensed 503A pharmacy as a bridge while the exception is reviewed.

Is Compounded Alendronate Legal in North Carolina?

Compounded alendronate is legal in North Carolina when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The NC Board of Pharmacy licenses and inspects these facilities, and compounding of commercially available drug substances is permitted under federal law (21 U.S.C. Section 503A) when the final product meets specific conditions [19].

The FDA's guidance on compounding distinguishes between 503A pharmacies (patient-specific, smaller volume) and 503B outsourcing facilities (larger scale, hospital supply). Alendronate in the commercial 70 mg oral tablet form is not on the FDA's 503A bulks list of substances that may be compounded without restriction, but compounding pharmacies can prepare alendronate in alternative strengths or forms under a valid prescription when there is a documented clinical need, such as a patient who cannot swallow standard tablets or who requires a non-standard dose [20].

For North Carolina patients, the practical implication is that a compounding pharmacy can prepare alendronate in a liquid, powder, or alternative-strength form for patients with specific clinical needs. Some NC-based compounding networks have offered this at no cost to patients enrolled in certain assistance programs, effectively making compounded alendronate $0 per month in those cases.

Patients should verify that any compounding pharmacy they use holds a current NC Board of Pharmacy license and is not on the FDA's list of pharmacies that received warning letters for quality violations [21]. The National Community Pharmacists Association maintains a directory of accredited compounders [22].

Telehealth Prescribing of Alendronate in North Carolina

A licensed physician or nurse practitioner practicing in North Carolina may prescribe alendronate via telehealth without a prior in-person visit, provided the prescriber complies with NC Medical Board telemedicine standards and the standard of care for prescribing an osteoporosis medication [23].

The NC Medical Board's telemedicine policy requires that prescribers establish a valid patient-provider relationship, which can be done via synchronous audio-video visit, before issuing a prescription [23]. Audio-only (telephone-only) visits do not meet the standard for new prescriptions under current NC rules.

For alendronate specifically, the standard of care typically requires evidence of bone density testing (DEXA scan) before starting therapy, or a documented history of fragility fracture. A telehealth provider can review uploaded DEXA reports and prior records to satisfy this requirement without an in-person encounter. The USPSTF recommends DEXA screening beginning at age 65 for women, and at younger ages when a validated fracture risk tool such as FRAX indicates elevated 10-year fracture probability [15].

HealthRX telehealth visits follow NC Medical Board standards and include physician review of bone density results before any alendronate prescription is issued.

Clinical Evidence Supporting Alendronate Use

The evidence base for alendronate spans more than 25 years of randomized controlled trial data and post-market surveillance.

The FIT trial (JAMA 1998, N=2,027) remains the landmark study. Women randomized to alendronate 5 mg daily (later increased to 10 mg) over a median 2.9 years showed a 28% reduction in all clinical fractures and a 51% reduction in hip fractures in the highest-risk subgroup, compared with placebo (P<0.001) [3]. Lumbar spine bone mineral density increased by 8.8% versus 0.6% with placebo at 36 months [3].

The FLEX extension trial (JAMA 2006, N=1,099) examined what happens when alendronate is stopped after 5 years. Women who continued for 10 total years had modestly higher spine BMD and lower risk of clinical vertebral fracture compared with those who discontinued at 5 years, though total fracture rates did not differ significantly between groups [24]. This finding shaped current AACE guidance recommending a drug holiday assessment at 5 years for lower-risk patients and continuation up to 10 years for higher-risk patients [4].

Vertebral fracture risk with alendronate is well-quantified. A 2011 Cochrane review of 11 trials (N=12,068) found that alendronate reduced radiographic vertebral fractures by 45% (relative risk 0.55; 95% CI 0.43 to 0.69) compared with placebo [25]. The same review found no statistically significant increase in serious adverse events versus placebo across the trial pool [25].

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures are recognized but rare adverse effects. The American Society for Bone and Mineral Research estimates ONJ incidence at 1 in 10,000 to 1 in 100,000 patient-treatment years in patients taking oral bisphosphonates for osteoporosis, a rate substantially lower than the fracture risk that alendronate prevents [26]. The FDA added an atypical femoral fracture warning to bisphosphonate labels in 2010 [27].

Adherence and Long-Term Use Considerations

Once-weekly dosing was introduced specifically to improve adherence. A randomized trial published in Osteoporosis International (N=500) found that patients were significantly more likely to remain on once-weekly alendronate at 12 months than on daily dosing (compliance rate 79% vs. 61%; P<0.05) [28]. Adherence matters because patients who discontinue alendronate within the first year lose most of the fracture protection benefit within 12 to 24 months [29].

Upper gastrointestinal side effects, including esophageal irritation, are the most common reason for discontinuation. The FDA label specifies that patients must take alendronate with at least 6 to 8 oz of plain water, remain upright for at least 30 minutes, and not lie down before eating the day's first food [2]. Patients with active esophageal disease or an inability to sit or stand for 30 minutes are not candidates for oral alendronate and should discuss intravenous bisphosphonate options such as zoledronic acid with their prescriber [5].

Calcium and vitamin D co-supplementation is expected. The AACE guidelines recommend 1,000 to 1 to 200 mg of elemental calcium daily (from diet plus supplement) and 800 to 1 to 000 IU of vitamin D3 daily in patients receiving antiresorptive therapy [4]. The Office of Dietary Supplements notes that most American adults consume less than 750 mg of dietary calcium per day, meaning supplementation is routinely needed [30].